Avg weight loss clinic
€ 43
€200-2000
Mounjaro, a weekly injectable medication, falls under the category of GLP-1 drugs, similar to Novo Nordisk's Wegovy.
While primarily used for patients with type 2 diabetes, Mounjaro also exhibits potential as a weight-loss medication.
Clinical trials have demonstrated the effectiveness of tirzepatide in reducing haemoglobin A1C levels and aiding in weight loss. Early data suggests that it may even contribute to a decreased risk of cardiovascular events like heart attacks or strokes, although a conclusive trial on this matter is still ongoing.
To achieve optimal results, Mounjaro should be utilised with lifestyle modifications, such as dietary adjustments, improved sleep patterns, and regular exercise. Professional coaching and expert support are expected to enhance the drug's efficacy.
The recommended initial dose of Mounjaro is 2.5 mg, with the option to gradually increase the dosage by 2.5 mg increments every four weeks, as long as it is well tolerated. The maximum weekly dose should not exceed 15 mg. Healthcare providers are responsible for prescribing and monitoring the appropriate dosage adjustments, aligning them with patients' blood sugar control, weight loss, and overall metabolic health objectives.
Mounjaro has indeed garnered significant attention for its exceptional attributes. Even before its approval, the results from clinical trials were making headlines, and with good reason. Tirzepatide, the critical component of Mounjaro, has surpassed some competitors in two studies, delivering outstanding outcomes. Further details about these trials and their remarkable findings are outlined below.
In a head-to-head trial conducted in 2021, Mounjaro by Eli Lilly demonstrated superior efficacy in controlling blood sugar levels and facilitating weight loss compared to Novo Nordisk's Ozempic (semaglutide). The SURPASS-2 trial spanned 40 weeks, during which participants experienced notable reductions in A1C levels. On average, these reductions reached up to 2.30 percentage points from their baseline, surpassing the results achieved with semaglutide, which showed a decrease of 1.86 percentage points.
Adding to the intrigue, the same trial unveiled intriguing findings regarding weight loss. Tirzepatide exhibited more significant reductions in body weight than semaglutide, with up to 5.5 kg more weight loss observed with the former. Researchers propose that this disparity may be attributed to the unique dual action of tirzepatide.
A summary article published in the New England Journal of Medicine affirms, "In patients with type 2 diabetes, the combination of a glucose-dependent insulinotropic polypeptide receptor and GLP-1 receptor agonist in a single molecule may exert a more significant impact on glucose levels and weight management than selective GLP-1 receptor agonists.
The highly-publicized SURMOUNT-1 trial focused on evaluating the effectiveness of Mounjaro® specifically for weight loss and the management of obesity. The results were nothing short of impressive. By week 72, participants achieved remarkable average weight loss percentages: 15.0% for those receiving 5 mg, 19.5% for those receiving 10 mg, and 20.9% for those receiving a 15 mg dose. In contrast, participants in the placebo group experienced a weight loss of only 3.1%.
In an earlier study conducted in 2018, different doses of Lilly's tirzepatide were compared to dulaglutide, also known as Trulicity. The study revealed that tirzepatide exhibited significantly superior efficacy in glucose control and weight loss compared to dulaglutide. Moreover, tirzepatide demonstrated an acceptable safety and tolerability profile, with side effects similar to those observed with dulaglutide. Overall, tirzepatide was well tolerated by participants in the study.
In various trials involving Mounjaro, tirzepatide was pitted against a placebo or compared to more traditional therapies, including two long-acting insulin analogues. In all instances, the highest dose of tirzepatide (15 mg/week) outperformed the competing treatments in reducing A1C levels and facilitating weight loss.
Mounjaro (tirzepatide) is administered via a convenient pen injector syringe, allowing easy subcutaneous injections. The injections can be self-administered in the comfort of your home without needing a healthcare provider or clinician to be present. The process is straightforward and user-friendly.
To administer Mounjaro (tirzepatide), you will inject the medication into the fatty tissue just beneath the skin's surface. It should be injected once weekly, ideally at the same time of day. For storage, Mounjaro (tirzepatide) should be kept in a refrigerator within the temperature range of 36°F to 46°F (2°C to 8°C).
If your doctor prescribes Mounjaro (tirzepatide), they will guide you through injecting it into your belly or upper thigh. If you cannot administer the injection yourself, someone else can inject the medication into your upper arm.
Rarely occurring, the side effects of Mounjaro (tirzepatide) are generally mild, with nausea or indigestion being the most commonly reported. These symptoms typically subside within the first month of starting the medication.
Other potential side effects of Mounjaro (tirzepatide) may include vomiting, diarrhoea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain. It is important to note that in studies conducted on rats, Mounjaro (tirzepatide) has been shown to cause thyroid C-cell tumours. However, it is currently unknown whether Mounjaro (tirzepatide) can lead to the development of such tumours, including medullary thyroid cancer, in humans. Consequently, individuals with a personal or family history of medullary thyroid cancer or those diagnosed with Multiple Endocrine Neoplasia syndrome type 2 should not use the medication.
It is worth mentioning that Mounjaro has not been specifically studied in patients with a history of pancreas inflammation (pancreatitis), and it is not indicated for use in individuals with type 1 diabetes.
Please remember that the side effects above do not encompass all possible adverse reactions associated with Mounjaro®. If you encounter any side effects that become bothersome or persist, it is essential to consult your healthcare provider. They can provide guidance, offer recommendations, and provide supportive care for any concerns that may arise. If you experience an allergic reaction, such as anaphylaxis or shortness of breath, it is crucial to seek immediate medical attention.
Mounjaro is a prescription medication that is safe and effective when used as directed. Knowing the warnings and contraindications associated with Mounjaro before starting treatment is essential, like all prescribed medications. Your doctor will provide a comprehensive discussion of these factors and can address any specific questions you may have regarding the risks of Mounjaro based on your unique health and medical history.
The limitations, contraindications, and warnings listed below have been carefully considered.
Mounjaro is a medication that is an adjunct to diet and exercise, specifically designed to enhance glycemic control in adults diagnosed with type 2 diabetes mellitus. It is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist.
Mounjaro should not be used in patients who have:
These conditions are contraindications for using Mounjaro, and it is crucial to avoid its administration in patients with these specific medical histories or hypersensitivity to tirzepatide.
Please be aware of the following important information regarding the use of Mounjaro:
When it comes to new treatments or medications that generate excitement in the medical weight loss field, it's natural to approach them with scepticism. However, Mounjaro stands apart by providing substantial evidence and impressive clinical trial results to substantiate its claims.
Here's a brief overview of what you should know about Mounjaro:
Mounjaro represents a groundbreaking advancement in weight loss and diabetes treatment, supported by compelling clinical trials and promising outcomes.
Several other medications in the GLP-1 category can be used for weight loss alongside Mounjaro (tirzepatide). These include:
These medications provide additional options for individuals seeking weight loss treatment and are prescribed based on individual needs and medical considerations.
Refill Prescription
UTI
Birth Control
STD
ED
Hair Loss
Malaria